These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
520 related articles for article (PubMed ID: 32605718)
41. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333 [TBL] [Abstract][Full Text] [Related]
42. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611 [TBL] [Abstract][Full Text] [Related]
43. KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Ghidini M; Personeni N; Bozzarelli S; Baretti M; Basso G; Bianchi P; Tronconi MC; Pressiani T; Grizzi F; Giordano L; Malesci A; Alloisio M; Laghi L; Santoro A; Rimassa L Cancer Med; 2016 Feb; 5(2):256-64. PubMed ID: 26715198 [TBL] [Abstract][Full Text] [Related]
44. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311 [TBL] [Abstract][Full Text] [Related]
45. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. Nadal E; Chen G; Prensner JR; Shiratsuchi H; Sam C; Zhao L; Kalemkerian GP; Brenner D; Lin J; Reddy RM; Chang AC; Capellà G; Cardenal F; Beer DG; Ramnath N J Thorac Oncol; 2014 Oct; 9(10):1513-22. PubMed ID: 25170638 [TBL] [Abstract][Full Text] [Related]
46. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC. Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052 [TBL] [Abstract][Full Text] [Related]
47. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
49. Use of a High-Throughput Genotyping Platform (OncoMap) for Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720 [TBL] [Abstract][Full Text] [Related]
50. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Zhu G; Pei L; Xia H; Tang Q; Bi F Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312 [TBL] [Abstract][Full Text] [Related]
51. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825 [TBL] [Abstract][Full Text] [Related]
52. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases. Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364 [TBL] [Abstract][Full Text] [Related]
53. Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer. Steele CW; Whittle T; Smith JJ Chin Clin Oncol; 2019 Oct; 8(5):53. PubMed ID: 31597434 [TBL] [Abstract][Full Text] [Related]